In 2000, the FDA approved and certified 15 ng/mL is the upper limit of ERBB2 in the serum of healthy subjects, thus pushing the medical community to use such a value as a reliable indicator of anti-tumor treatment efficiency. The gene discussed is ERBB2; the disease is neoplasm.